JenKem Technology Co., Ltd. Report issue

For profit Phase 2
Founded: Plano Texas United States (2001)

Organization Overview

First Clinical Trial
2018
NCT04366648
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

JenKem Technology Co., Ltd.

Active Ingredients

Drugs in Phase 2 Trials (1)

etirinotecan pegol (Onzeald) (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Neoplasms (Phase 1)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 1